【大河财立方 记者 王鑫】2025年的中国医药行业,在资本涌动与激烈竞争格局下,谱写了一曲“冰与火之歌”。一边是创新药迎来技术、资本与市场的全面爆发;另一边,疫苗行业则深陷激烈的价格内卷,业绩集体亏损。从药企扎堆赴港上市寻求融资,到产业巨头通过并购加速整合,整个医药行业正在裂变与重组中,深刻重塑着未来的竞争新版图。创新药大爆发2025年,是中国创新药在技术、市场、国际化领域大爆发的一年。数据显示,...
Source Link【大河财立方 记者 王鑫】2025年的中国医药行业,在资本涌动与激烈竞争格局下,谱写了一曲“冰与火之歌”。一边是创新药迎来技术、资本与市场的全面爆发;另一边,疫苗行业则深陷激烈的价格内卷,业绩集体亏损。从药企扎堆赴港上市寻求融资,到产业巨头通过并购加速整合,整个医药行业正在裂变与重组中,深刻重塑着未来的竞争新版图。创新药大爆发2025年,是中国创新药在技术、市场、国际化领域大爆发的一年。数据显示,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.